CoChat

Post hoc analysis of the Exenatide‐ PD trial—Factors that predict response

Athauda, Dilan, Maclagan, Kate, Budnik, Natalia, Zampedri, Luca, Hibbert, Steve, Aviles‐Olmos, Iciar, Chowdhury, Kashfia, Skene, Simon S., Limousin, Patricia, Foltynie, Thomas · 2019 · European Journal of Neuroscience
Cited by 77

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Exenatide, a glucagon‐like peptide‐1 agonist and a licensed treatment for Type 2 diabetes significantly reduced deterioration in motor symptoms in patients with Parkinson's disease in a randomized, placebo‐controlled trial. In addition, there were trends favouring the exenatide group in assessments of nonmotor symptoms, cognition, and quality of life. The aim of this exploratory post hoc analysis was to generate new hypotheses regarding (a) whether candidate baseline factors might predict the magnitude of response to exenatide; and (b) whether the beneficial effects of exenatide reported for the overall population are consistent in various subgroups of patients. Univariate and multivariate analyses were conducted to determine possible predictors of motor response to exenatide in this cohort. Potential treatment by subgroup interactions for changes in; motor severity, nonmotor symptoms, cognition, and quality of life after 48‐weeks treatment with exenatide were evaluated among post hoc subgroups defined by age, motor phenotype, disease duration, disease severity, body mass index ( BMI ), and insulin resistance. In the subgroup analyses, exenatide once‐weekly was associated with broadly improved outcome measures assessing motor severity, nonmotor symptoms, cognition, and quality of life across all subgroups, however, tremor‐dominant phenotype and lower Movement Disorder Society‐Sponsored Revision of the Unified Parkinson's Disease Rating Scale ( MDS ‐ UPDRS ) Part‐2 scores predicted greatest motor response to exenatide and there was an indication that patients with older age of onset and disease duration over 10 years responded less well. While patients with a range of demographic and clinical factors can potentially benefit from exenatide once‐weekly, these data support an emphasis towards recruiting patients at earlier disease in future planned clinical trials of gluacagon‐like peptide‐1 ( GLP ‐1) receptor agonists in Parkinson's disease ( PD ).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/ejn.14096

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 77

Metadata

Authors
Athauda, D., Maclagan, K., Budnik, N., Zampedri, L., Hibbert, S., Aviles‐Olmos, I., Chowdhury, K., Skene, S. S., Limousin, P., & Foltynie, T.
Venue
European Journal of Neuroscience
Publisher
Wiley
Published
2018-10-06
Volume
49
Issue
3
Pages
410-421
ISSN
  • 0953-816X (ISSN-L)
  • 1460-9568
OpenAlex
W2887342138
Cited by
77
References
5
FWCI
3.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Post hoc analysis of the Exenatide‐ PD trial—Factors that predict response. https://app.cochat.ai/papers/10.1111/ejn.14096
The paper
Athauda, D., Maclagan, K., Budnik, N., Zampedri, L., Hibbert, S., Aviles‐Olmos, I., Chowdhury, K., Skene, S. S., Limousin, P., & Foltynie, T. (2019). Post hoc analysis of the Exenatide‐ PD trial—Factors that predict response. European Journal of Neuroscience. https://doi.org/10.1111/ejn.14096

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.